News | Prostate Cancer | March 17, 2016

Higher Volume Radiation Facilities Associated with Better Prostate Cancer Survival

New research finds improvement in overall survival rates among men with aggressive prostate cancer who were treated with radiation at a facility that frequently performs that treatment

high-risk prostate cancer, radiation therapy, high volume facilities, Brigham and Women's Hospital study

March 17, 2016 — New research finds improvement in overall survival rates among men with aggressive prostate cancer who were treated with radiation at a facility that frequently performs that treatment.

In a new study led by researchers at Brigham and Women's Hospital, investigators looked at men with aggressive prostate cancer who were treated with radiation as well as the case volume of the facility at which they were treated. They found that receiving radiation at a facility that treats a high volume of prostate cancer patients with radiation was associated with improved overall survival.

These findings are published online and appear in the March 15, 2016 issue of the International Journal of Radiation Oncology, Biology, and Physics.

While it is well established that hospital volume and surgeon volume are associated with better outcomes for patients who require surgery for their cancer, relatively little is known about whether this positive association is also true for cancer patients who require radiation treatment.

"Our paper shows that experience counts," said Paul Nguyen, M.D., a physician researcher in the Department of Radiation Oncology at Brigham and Women's Hospital and corresponding author of the new paper. "For men with aggressive prostate cancer, survival is improved if they receive their radiation treatments at a high volume facility as opposed to a lower volume facility."

Using a large cancer database, researchers analyzed data from 19,565 high-risk prostate cancer patients who were treated with radiation at 1,099 facilities. This study focused on high-risk prostate cancer because these patients are much more likely to die from their disease than men with low- or intermediate-risk disease. After adjusting for stage of the disease, age, race, insurance status and other patient factors, researchers found that patients who received radiation at higher-volume facilities consistently had better survival rates than those treated at lower-volume facilities. For example, patients treated at a facility in the top 20 percent by prostate radiation volume (>43 patients per year) versus bottom 80 percent achieved a 76 percent versus 74 percent seven-year overall survival.

"We know that a surgeon who does a high volume of a specific procedure has better outcomes, and now we see that same trend when it comes to radiation therapy," Nguyen said. "At a higher volume facility, not only will the radiation oncologist have more experience at designing and delivering the appropriate treatment fields, but the multidisciplinary team of pathologists, radiologists, urologists and medical oncologists will have greater expertise in making accurate diagnoses and tailoring the systemic therapy regimen to ensure the best-possible outcome for the patient."

Researchers note that the study was observational, and while they adjusted for every known patient-related, socioeconomic and tumor-related factor available in the database, it is still possible that other factors that could not be fully controlled for are contributing to the outcomes observed. Future studies in other datasets are being planned to corroborate the strong effect seen here.

This research was funded by the Prostate Cancer Foundation, Fitz's Cancer Warriors, David and Cynthia Chapin, Hugh Simons in Honor of Frank and Anne Simons, Scott Forbes and Gina Ventre Fund, Jeffrey Campbell in Honor of Joan Campbell, and a grant from an anonymous family foundation.

For more information: www.redjournal.org

Related Content

RayStation Replacing Existing Treatment Planning System at Leeds Cancer Centre
News | Treatment Planning | September 24, 2018
RaySearch recently strengthened its position in the U.K. market with a major order for the treatment planning system...
Turkish Hospital Begins MR-Guided Radiation Therapy With Viewray MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | September 21, 2018
ViewRay Inc. announced that Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with ViewRay's...
Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...
Exact Imaging Partners to Improve Prostate Cancer Detection With Artificial Intelligence
News | Prostate Cancer | September 19, 2018
Exact Imaging, makers of the ExactVu micro-ultrasound platform, has partnered with U.K.-based Cambridge Consultants to...
Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Videos | Radiation Therapy | September 07, 2018
A discussion with Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Gr
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...

Image courtesy of IBA

Feature | Radiation Oncology | September 07, 2018 | By Jeff Zagoudis
According to the latest statistics from the American Cancer Society (ACS), almost 165,000 new cases of prostate cancer...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Check-Cap Announces Interim Results of European Study of C-Scan System Version 3
News | Colonoscopy Systems | September 04, 2018
Check-Cap Ltd. announced the interim results for its post-CE approval study of the C-Scan system Version 3, an...